 
              Eris Lifesciences Limited has reported Consolidated financial results for the period ended June 30, 2024.
Financial Results (Q1 FY2025) - QoQ Comparison 
The company has reported total income of Rs.  721.36 crores during the period ended June 30, 2024 as compared to Rs. 566.08 crores during the period ended March 31, 2024.
The company has posted net profit / (loss) of Rs. 83.18 crores for the period ended June 30, 2024 as against net profit / (loss) of Rs. 70.96 crores for the period ended March 31, 2024.
The company has reported EPS of Rs. 6.10 for the period ended June 30, 2024 as compared to Rs. 5.21 for the period ended March 31, 2024.
                    
       | Total Income | ₹ 721.36 crs | ₹566.08  crs |  27.43% | 
      | Net Profit | ₹83.18 crs | ₹70.96  crs |  17.22% | 
      | EPS | ₹6.10 | ₹5.21 |  17.08% | 
Financial Results  (Q1 FY2025) - YoY Comparison  The company has reported total income of Rs. 721.36 crores during the period ended June 30, 2024 as compared to Rs.467.61 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs.83.18 crores for the period ended June 30, 2024 as against net profit / (loss) of Rs.94.86 crores for the period ended June 30, 2023.
The company has reported EPS of Rs.6.10 for the period ended June 30, 2024 as compared to Rs.6.97 for the period ended June 30, 2023.
                    
      | Total Income | ₹ 721.36 crs | ₹467.61 crs |  54.27% | 
      | Net Profit | ₹83.18  crs | ₹94.86 crs |  -12.31% | 
      | EPS | ₹6.10 | ₹6.97 |  -12.48% | 
 
Shares of Eris Lifesciences Limited was last trading in BSE at Rs. 1121.95 as compared to the previous close of Rs. 1119.05. The total number of shares traded during the day was 8778 in over 1198 trades.
The stock hit an intraday high of Rs. 1136.95 and intraday low of 1095.20. The net turnover during the day was Rs. 9838559.00.
              
Source : Equity Bulls
              Keywords
                                       
                                               ErisLifesciences 
                                               Q1FY25 
                                               FY2025 
                                               Q1FY2025 
                                               ResultUpdate